Assessment of Coagulation and Thrombocyte Function After Termination of Ticagrelor

• Register: ClinicalTrials.gov
• Last refreshed on: 6 October 2015
• Main ID: NCT02297971
• Date of registration: 18/11/2014
• Prospective Registration: No
• Primary sponsor: Örebro University, Sweden
• Public title: Assessment of Coagulation and Thrombocyte Function After Termination of Ticagrelor BRILIQUE
• Scientific title: Assessment of Coagulation and Thrombocyte Function After Termination of Ticagrelor in Patients Who Have Previously Undergone PCI Procedures and Insertion of Coronary Stents
• Date of first enrolment: September 2013
• Target sample size: 25
• Recruitment status: Completed
• URL: https://clinicaltrials.gov/show/NCT02297971
• Study type: Observational
• Study design: Observational Model: Case-Only, Time Perspective: Prospective
• Phase: N/A

Countries of recruitment

Sweden

Contacts

• Name: Anil Gupta, MD, PhD
• Affiliation: Örebro University

Key inclusion & exclusion criteria

Inclusion Criteria:

- Patients who are on the Cardiology Clinic's database at the University Hospital, Örebro
and shall terminate ticagrelor after one year following PCI and stent placement would be
identified and offered to take part in this study.

Exclusion Criteria:

- Non-responders (not partial responders) to ticagrelor would be excluded from the study.
Additionally, patients who are either taking NSAID's regularly or during the last 2 weeks
prior to study start would also be excluded as those who have language or cognitive
limitations.



Age minimum: 45 Years
Age maximum: 85 Years
Gender: Both

Health Condition(s) or Problem(s) studied

Coronary Stents

PCI

Primary Outcome(s)

Platelet aggregometry [Time Frame: 0 - 10 days]

Secondary Outcome(s)

Thromboelstography [Time Frame: 0-10 days]

Coagulation function tests [Time Frame: 0-10 days]

Secondary ID(s)

2013/001

Source(s) of Monetary Support

Please refer to primary and secondary sponsors